Fulgent Genetics (FLGT) Projected to Post Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is anticipated to post its quarterly earnings results before the market opens on Friday, February 28th. Analysts expect Fulgent Genetics to post earnings of ($0.31) per share and revenue of $75.39 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Fulgent Genetics Price Performance

Shares of Fulgent Genetics stock opened at $16.24 on Thursday. Fulgent Genetics has a one year low of $15.99 and a one year high of $25.48. The stock’s 50-day moving average is $17.43 and its 200 day moving average is $19.58. The firm has a market cap of $496.73 million, a price-to-earnings ratio of -2.94 and a beta of 1.39.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Piper Sandler cut their target price on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. StockNews.com lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.